NASDAQ:BRTX

Biorestorative Therapies Stock News

Healthcare > Biotechnology

Buy BRTX

*Your capital is at risk

$0.339

-0.0150 (-4.23%)

At Close: Jun 03, 2026

BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease

07:30am, Monday, 05'th Feb 2024

— Preliminary data includes 26 and 52-week follow-up end points as part of ongoing Phase 2 trial — — Company to host webcasted conference call today at 8:30am EST — MELVILLE, N.Y., Feb. 05, 20

BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting

07:30am, Thursday, 01'st Feb 2024

— Blinded data from the ongoing Phase 2 clinical trial of BRTX-100 to be described in poster presentation — — Company to host webcasted conference call to review data on February 5, 2024 at 8:30

BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program

09:15am, Tuesday, 12'th Dec 2023

--Notice of allowance will be the fourth U.S. patent granted under Company's ThermoStem ® program targeting obesity and metabolic disorders, including type 2 diabetes-- MELVILLE, N.Y., Dec. 12, 2023

BioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York City

12:10pm, Monday, 09'th Oct 2023

MELVILLE, NY., Oct. 09, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRetorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies

Roth MKM Analyst Projects An Impressive Price Target of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says “Low Valuation Undeserved”

09:00am, Monday, 18'th Sep 2023

MELVILLE, NY / ACCESSWIRE / September 18, 2023 / BioRestorative Therapies Inc. (NASDAQ:BRTX) ("BioRestorative") is a clinical-stage biotech company that is developing cell-based therapies to treat chr

BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics

09:00am, Tuesday, 12'th Sep 2023

-- BioRestorative to Leverage its Core Competencies in Cell Biology and Manufacturing to S upply B iologics for C osmetic A pplications in Strategic Agreement

BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease

08:30am, Friday, 08'th Sep 2023

--Site activation allows for patients in the S tate of New York to participate in the BRTX-100 t rial —

Insider Buying Alert: Lance Alstodt Acquires 4200 Shares of BioRestorative Therapies Inc (BRTX)

12:01pm, Wednesday, 26'th Jul 2023

On July 25, 2023, Lance Alstodt, President, CEO, COB, and 10% Owner of BioRestorative Therapies Inc ( BRTX , Financial), made a significant purchase of 4200 shares of the company's stock. This move is

BioRestorative Therapies Receives Unanimous Recommendation from Data Safety Monitoring Board (DSMB) to Continue its Phase 2 Clinical Trial without any Changes

11:00am, Wednesday, 28'th Jun 2023 InvestorsHub

BioRestorative Therapies Receives Unanimous Recommendation from Data Safety Monitoring Board (DSMB) to Continue its Phase 2 Clinical Trial without any Changes No Dose Limiting Toxicity (DLT) was Observed in the Patients in the Safety Run-In Segment of Study DSMB Recommendation Allows for Open Enrollment MELVILLE, N.Y. -- June 27, 2023 -- InvestorsHub NewsWire -- BioRestorativ...

BioRestorative Therapies, Inc. to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET

07:00am, Friday, 16'th Jun 2023

MELVILLE, NY., June 16, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRetorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by